Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 14.62$. Average daily volumn in 3 months 731.74k. Market cap 13.92B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 15.39$. Total volume : 1.64M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
15.39$
Change
0.94
Volume
1.64M

Previous Close14.45
Open14.73
Day Range14.72-15.71
Bid15.11 x 800
Ask15.45 x 1.3k
Volume1.64M
Average Volume731.74k
Market Cap13.92B
Beta0.10
52 Week Range14.01-20.49
Trailing P/E31.47
Foward P/E10.19
Dividend (Yield %)5.20%
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2020 were 5.34B an increase(0%) over the years 2019 revenue that were of 5.1B. In 2020 the company's total earnings were 618.55M while total earnings in 2019 were 625.15M(-1.12%).


Loading ...



Organization

Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.

Grifols, S.A._logo

Market Cap:
13.92B
Revenue:
5.34B
Total Assets:
15.27B
Total Cash:
579.65M


News about "Grifols, S.A."

Grifols Buys Biotest as Creat Pushed to Exit Blood-Plasma Stakes_image

Grifols Buys Biotest as Creat Pushed to Exit Blood-Plasma Stakes

Grifols SA agreed to buy Biotest AG for about 1.6 billion euros ($1.9 billion), pouncing after U.S. regulators pushed back on Chinese shareholder Creat Group Corp.โ€™s expansion into the blood-plasma ...

Source from : YAHOO!Finance - 1 days ago


Grifols, S.A. (GRFS)

Grifols, S.A. Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Indicate by check mark if the registrant is submitting the Form 6-K in ...

Source from : Seeking Alpha - 1 days ago


Grifols S.A. (GRFS) is on the roll with an average volume of 716.87K in the recent 3 months

Grifols S.A. (GRFS) is priced at $15.33 after the most recent trading session. At the very opening of the session, the stock price was $14.23 and reached a high price of $14.51, prior to closing the ...

Source from : investchronicle - 1 days ago


Grifols to buy majority stake in Biotest for $1.3 billion_image

Grifols to buy majority stake in Biotest for $1.3 billion

The operation assessed Biotestโ€™s equity and enterprise value at approximately EUR 1.6 billion and EUR 2 billion, respectively. Upon completion of the transaction, Grifols will i ...

Source from : poandpo.com - 1 days ago


Creat Said to Near Sale of Blood Plasma Firm Biotest to Grifols_image

Creat Said to Near Sale of Blood Plasma Firm Biotest to Grifols

Chinaโ€™s Creat Group Corp. is nearing the sale of German blood-plasma supplier Biotest AG to Grifols SA of Spain, according to people familiar with the matter.

Source from : Bloomberg - 2 days ago


Grifols acquires Tiancheng Pharmaceutical Holdings, the largest shareholder of Biotest, to increase patients' access to plasma therapies_image

Grifols acquires Tiancheng Pharmaceutical Holdings, the largest shareholder of Biotest, to increase patients' access to plasma therapies

Grifols agrees to acquire the existing share capital of Tiancheng (Germany) Pharmaceutical Holdings for EUR 1,100 million. Tiancheng (Germany) ...

Source from : PR Newswire - 1 days ago


Grifols to Acquire Germany's Biotest for $1.3 Bln

By Joshua Kirby Spanish pharmaceutical company Grifols SA said Friday that it has reached an agreement to acquire a majority stake in German peer Biotest ...

Source from : MarketWatch - 1 days ago


Grifols Grabs German Plasma Co. At โ‚ฌ2B Enterprise Value

Spanish health care giant Grifols SA, represented by Osborne Clarke and Proskauer Rose, will take control of German therapeutic drugmaker Biotest AG in a deal that features an enterprise value of โ‚ฌ2 ...

Source from : Law360 - 1 days ago


DJ DGAP-Adhoc: Biotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG

Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG 17-Sep-2021 / 12:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the ...

Source from : Sharecast - 1 days ago


Grifols To Acquire Biotest AG In Germany

Grifols (GRFS) has reached an agreement with Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng ...

Source from : Business Insider - 1 days ago


Spain's Grifols to buy rival Biotest for up to 1.6 billion euros

Spanish pharmaceuticals company Grifols has agreed to buy a controlling stake in Biotest and made a bid for the rest of its shares in a deal that would value its German rival at 1.6 billion euros ($1.

Source from : Reuters on MSN.com - 1 days ago


Grifols Bids $1.9 Billion for Blood-Plasma Firm Biotest

Grifols SA agreed to buy German blood-plasma supplier Biotest AG for about 1.6 billion euros ($1.9 billion) as Chinese shareholder Creat Group Corp. unwinds assets following an acquisition spree.

Source from : Yahoo Finance - 1 days ago


Grifols acquires Tiancheng Pharmaceutical Holdings_image

Grifols acquires Tiancheng Pharmaceutical Holdings

Grifols, a global healthcare leader in plasma-derived medicines, Sep. 17 entered into the agreement with Tiancheng International Investment Ltd. (Hong Kong) to acquire 100% of the shares of Tiancheng ...

Source from : akm.ru - 1 days ago


Grifols S.A. Cl B

Grifols SA, Instituto Grifols SA, Grifols USA, Inc., Arrahona Optimus SL Raimon Grifols Roura Joint Chief Executive Officer & Executive Director Grifols SA, Grifols USA, Inc., Squadron Reinsurance ...

Source from : Wall Street Journal - 24 days ago


Urgent need for more plasma donors

Grifols is a global health-care company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines. Plasma is the largest part ...

Source from : KSTU - 3 days ago


Grifols SA ADR G0FB

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Source from : Morningstar%2c Inc. - 13 days ago


Deals of the day-Mergers and acquisitions

Sept 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1340 GMT on Friday: ** Brazilian logistics company Log-In said its largest shareholder, asset manager ...

Source from : Reuters on MSN.com - 1 days ago


Subcutaneous Immunoglobulin Market 2021 Vital Drivers, Research Objectives, Future Aspects| Biotest AG, CSL Limited, Grifols

Pune, Maharashtra, India, September 9 2021 (Wiredrelease) MarketResearch.Biz โ€“:The worldwide market research report Subcutaneous Immunoglobulin Market scrutinizes the marketโ€™s current trends ...

Source from : Digital Journal - 9 days ago


The next pandemic: How Triangle researchers are looking beyond Covid-19

โ€œPeople forget โ€ฆ the horrors of the scenario fade over time.โ€ Baric said that right now thereโ€™s a lot of interest both from the government and private corporations in developing broad ...

Source from : The Business Journals - 26 days ago


Biotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG

Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG 17-Sep-2021 / 12:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ...

Source from : Yahoo Finance - 1 days ago


Grifols: Q2 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Thursday reported earnings of $164.9 million in its second quarter. The Barcelona, Spain-based company said it had profit of 24 cents per share.

Source from : The Register Citizen - 1 month ago


Grifols S.A. (GRFS) Just Got Our Attention

Grifols S.A. (NASDAQ:GRFS) went down by -0.41% from its latest closing price compared to the recent 1-year high of $20.49. The companyโ€™s stock price has collected 2.94% of gains in the last five ...

Source from : newsheater - 2 month ago


Grifols S.A. -- Moody's says Grifols' ratings unchanged following lenders' consent on certain debt terms' amendments

ยฉ 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and ...

Source from : Business Insider - 1 month ago


Global Propionic Acidemia Market Growth Analysis, Latest Trends and Forecast till 2027|Cardiva Grifols SA, CSL Behring, Octapharma AG

id=389589 Top Key Players Included in Propionic Acidemia Market Report: Cardiva Grifols SA, CSL Behring, Octapharma AG, Sanquin, Kedrion S.p.A, Shire, China Biologic Products Holdings, Inc Within ...

Source from : openpr.com - 1 month ago


Grifols presents its latest Alzheimer's clinical trial data

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...

Source from : ADVFN - 1 month ago


The MX Q&A: Timothy Still, Accumetrics

On the business front Still and his team have been pursuing international sales partnerships. Accumetrics signed agreements in September 2009 with Grifols S.A. for exclusive distribution of the ...

Source from : MD&M East - 1 month ago


Grifols SA - ADR - Level III

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...

Source from : U.S. News & World Report - 1 year ago


News - Grifols

Spanish plasma specialist Grifols is to establish a global R&D hub in Andorra, focused on the human immuneโ€ฆ Spanish drugmaker Grifols today announced the closing of its agreement with GigaGen to ...

Source from : The Pharma Letter - 1 year ago


Grifols SA - ADR - Level III

Financial advisors who assume this role conduct a fact-finding mission to determine client needs.

Source from : U.S. News & World Report - 1 year ago


European shares fall for the third week in a row_image

European shares fall for the third week in a row

Latest financial technology news, fintech news, fin tech news, open banking newsโ€‹, banking news, blogs opinion, analysis on Fintech Zoom.

Source from : fintechzoom - 11 hours ago


Europe stocks struggle, as inflation hits a decade high and miners hit by downgrades at UBS_image

Europe stocks struggle, as inflation hits a decade high and miners hit by downgrades at UBS

Stocks were headed for a flat finish to the week amid struggles for mining companies, and a jump in euro-area inflation.

Source from : MarketWatch on MSN.com - 1 days ago


European Stocks Close Notably Lower On Growth Worries

European stocks ended on a negative note on Friday as signs of slowing global growth amid a surge in coronavirus cases in several countries across the world, and introduction of tighter regulations on ...

Source from : Nasdaq - 1 days ago


GRLSbn.MC - Grifols SA Profile | Reuters

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes ...

Source from : Reuters - 4 years ago


European Shares Rise As Travel Stocks Climb

European stocks rose on Friday and were on track for weekly gains, as travel and tourism stocks gained ground amid reports that Britain will consider easing COVID-19 rules for international travel ...

Source from : Nasdaq - 1 days ago


Intravenous Immunoglobulin Market projected to expand at a CAGR of 8.1% from 2018 to 2026

Transparency Market Research (TMR) ( has published a new report titled, โ€œIntravenous Immunoglobulin Market โ€“ Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018โ€“2026โ€. According ...

Source from : manometcurrent.com - 1 days ago


DAX Stock News Today โ€“ Europe stocks struggle, as inflation hits a decade high and miners hit by downgrades at UBS

DAX Stock News Today - Europe stocks struggle, as inflation hits a decade high and miners hit by downgrades at UBS - ...

Source from : fintechzoom - 23 hours ago


The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is expected to reach USD 21.58 billion by 2026

Reportlinker.com announces the release of the report "Immunoglobulins Market - Global Outlook & Forecast 2021-2026" ...

Source from : Benzinga.com - 2 days ago


Intravenous Antibodies Market is Dominated by North America and Europe_image

Intravenous Antibodies Market is Dominated by North America and Europe

According to a new report published by Allied Market Research titled Intravenous Antibodies Market by Type IgG IgA IgM IgE and IgD Application Immunodeficiency Diseases Chronic Inflammatory ...

Source from : openpr.com - 1 days ago


Global Blood Transfusion Devices Market By Product, By Blood Component, By End User, By Region, Competition, Forecast & Opportunities, 2026

Major players operating in the global blood transfusion devices market include Fresenius Kabi AG, Grifols S.A., Terumo Corporation, B. Braun Melsungen AG, Becton, Dickinson, Company, Immucor Inc ...

Source from : Yahoo Finance - 4 days ago


Hemophilia Drugs Market Research Report with Size, Share, Value,Trends, Outlook, Analysis, Latest Updates, Data, CAGR, and News 2020-2025

Some of the companies operating in the market are Pfizer Inc., CSL Limited, Grifols, S.A., Bioverativ Inc., Octapharma AG, FERRING Lร„KEMEDEL AB, and Aptevo Therapeutics. The emergence of COVID-19 ...

Source from : WBOC - 3 days ago